|Amylin Said to Draw First-Round Bids; PDI Announces New Business Win|
|By Mary Davila|
|Friday, 25 May 2012 19:16|
Amylin Pharmaceuticals Inc. (NASDAQ:AMLN), the diabetes drugmaker that’s up for sale, has received first-round bids from Sanofi (SAN) and Merck & Co. (NYSE:MRK) said three people familiar with the process.
The companies made offers of at least $25 a share, said the people, who declined to be identified as the deliberations are private. That would value Amylin at more than $4 billion, based on its shares outstanding as of April 26. Offers are due today for the San Diego-based company, whose medicines include Bydureon and Byetta, they said.
Takeda Pharmaceutical Co. and Bristol-Myers Squibb Co. (NYSE:BMY) have indicated to Amylin they also will make offers, the people said. Amylin began looking for suitors with Credit Suisse Group AG and Goldman Sachs Group Inc. after rejecting a $3.5 billion offer from Bristol-Myers this year, people with knowledge of the matter said last month.
“Diabetes is one of the last few monolithic market opportunities,” Michael King, an analyst with Rodman & Renshaw in New York, said today in a telephone interview. “All you have to do is look at the statistics. The numbers are enormous and growing.”
Pfizer Inc. (NYSE:PFE), AstraZeneca Plc (NYSE:AZN) and Roche Holding AG (PINK:RHHBY) had signed confidentiality agreements on Amylin’s sale process, people familiar with the matter said this month. It wasn’t clear whether they decided to move ahead with bids.
Spokesmen at Sanofi, Roche and AstraZeneca declined to comment. Representatives at Merck, Amylin, Pfizer and Bristol- Myers declined to comment. A U.S.-based spokeswoman for Takeda declined to comment.
Amylin rose 8.4 percent to $27.96 at the close in New York, the biggest single-day gain in a month.
PDI, Inc. (NASDAQ:PDII) announced the signing of a contract with a new customer to provide promotional services across PDI's multiple communications channels that will target primary care physicians. The contract is subject to FDA product approval. The contract is expected to generate total revenue to PDI of approximately $57 million over the life of the two-year agreement, with $10-$12 million to be recorded over the second half of 2012.
Under the agreement, PDI will provide an array of promotional services, including but not limited to dedicated sales teams, as well as teledetailing and digital communications through PDI's Group DCA division.
"We are delighted to have been selected by this new client to provide a wide range of promotional support," said Nancy Lurker, Chief Executive Officer of PDI, Inc. "In applying our multi-channel promotional capabilities, PDI looks forward to demonstrating the value, strategic flexibility and high return on investment that we can provide through our outsourcing services."
Access Plans, Inc. (OTCBB: APNC), a leading membership benefits marketing company, announced that the estimated amount of its previously announced special dividend is $0.08 per share.
Adia Nutrition, Inc. (PINKSHEETS: ADIA) started airing thousands of 30 and 60 second commercials across the country in more than 100 regions on networks including CNN, ESPN, FOX News Channel, TBS, The Learning Channel, TNT and USA Network.
BioScrip (NASDAQ: BIOS) today announced that the Company will present at the Jefferies 2012 Global Healthcare Conference to be held at the Grand Hyatt in New York City on June 4-7, 2012.
Daxor Corporation (NYSE MKT: DXR) (NYSE Amex: DXR), an investment company with medical instrumentation and biotechnology operations, filed a Form N-Q today disclosing its schedule of portfolio holdings as of March 31, 2012.
ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced today that its common stock has been approved for listing on the NYSE: MKT.
InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that the Company will be conducting a webcast of the Annual Shareholders Meeting scheduled for Wednesday, May 30, 2012 at 9:00 a.m. Eastern Daylight Time at One Broadway, 5th Floor, Cambridge, MA 02142.
InSite Vision Incorporated (OTCBB:INSV) will hold its Annual Meeting of Stockholders at 10:00 a.m. Pacific Time on Thursday, May 31, 2012 at the company's headquarters at 965 Atlantic Avenue, Alameda, California.
La Jolla Pharmaceutical Company (OTCQB: LJPC) (PINKSHEETS: LJPC) (the "Company" and "La Jolla") held its 2012 Annual Meeting of Stockholders on May 22.
Leading nutritional supplements creator and marketer iSatori Technologies, Inc. (OTCBB: IFIT), a wholly owned subsidiary of Integrated Security Systems, announces it will change its stock ticker symbol as of May 22, 2012, simplifying the code investors use to trade its shares.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, welcomes today’s launch in Rwanda of Africa’s first national rotavirus vaccination program with ROTATEQ® (rotavirus vaccine, live, oral, pentavalent), Merck’s vaccine for the prevention of rotavirus disease.
Mylan Inc. (Nasdaq: MYL) today announced that Mylan Specialty L.P., f/k/a Dey Pharma, L.P., has entered into an agreement with Sunovion Pharmaceuticals Inc., f/k/a Sepracor Inc., to resolve the parties' patent litigation relating to Sunovion's Brovana® product.
OmniComm Systems, Inc. (OTCBB: OMCM), one of the fastest growing companies in the Electronic Data Capture (EDC) marketplace, today announced that Veeda Clinical Research Inc., also known as Veeda Oncology®, has joined OmniComm's CRO Preferred Program, and as part of this program has signed an agreement to run their first study; a 27 month, phase I oncology trial.
PTS, Inc. (PINKSHEETS:PTSH) www.ptspi.com management and its subsidiary Navistar Global Logistics Ltd (Navistar) www.navistar.co.uk concerned with the recent trading patterns irregularities, and decline or erosion of its valuation and or share price brings attention to a certain financial report filed with OTC Markets of even date, namely: May 25, 2012 Officer/Director/Affiliate Stock Transactions
RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) reported that data showing that Thymosin beta 4 (Tβ4) “provides both neuroprotection and neurorestoration after traumatic brain injury (TBI),” was published in the current (May 2012) edition of the Journal of Neurosurgery, 116:1081–1092.
Rite Aid Corporation (NYSE:RAD) announced that its Board of Directors has elected John T. Standley, who is currently President, Chief Executive Officer and a member of the Company’s Board of Directors, to the additional position of Chairman of the Board, effective June 21, 2012 at the Company’s annual stockholder meeting.
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, today announced that data from studies of miRview® mets² in patients with Cancer of Unknown and Uncertain Primary ("CUP") were published online in The Oncologist in an article titled, "A second generation microRNA-based assay for diagnosing tumor tissue origin: An improved microRNA-based mets assay."
Safeguard Scientifics, Inc. (NYSE: SFE), a holding company that builds value in growth-stage life sciences and technology companies, today announced that it appointed Dr. Keith B. Jarrett to its board of directors.
Synergetics USA, Inc. (NASDAQ: SURG), a medical device company that designs, manufactures, and markets innovative microsurgical devices for ophthalmic and neurosurgical applications, today announced its upcoming participation in the following investor conferences: David M. Hable, President and CEO; Pamela G. Boone, Executive Vice President and CFO; and Jason Stroisch, Vice President of Marketing will meet with investors at the 9th Annual Craig-Hallum Institutional Investor Conference on Wednesday, May 30th in Minneapolis, Minnesota.
VentriPoint Diagnostics Ltd. (TSX VENTURE:VPT) (OTCQX:VPTDF) has installed its VMS™ heart analysis system at University Children's Hospital in Zurich, Switzerland for their Congenital Heart Disease clinics.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion by consensus recommending the approval of KALYDECO™ (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Whole Foods Market named Integrated Management Information, Inc. (OTCBB: INMG) the winner of its Quality Assurance Award in the grocer's inaugural Supplier Awards.